Evidence map›Paper›PMID 39970956›Full record

ArticleClinical genetics2025

Genotypic and Phenotypic Characterization of Seven Individuals With Predicted Bone Morphogenetic Protein 2 (BMP2) Haploinsufficiency.

Elin Stavrén-Eriksson, Anna Hammarsjö, Anna Lindstrand, Ann Nordgren, Giedre Grigelioniene, Maritta Hellström Pigg

Abstract read
In one paragraph

Article in Clinical genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elin Stavrén-ErikssonCentre for Clinical Research Sörmland, Uppsala University SE-Sweden, Uppasala, Sweden.
Anna HammarsjöDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Anna LindstrandDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.ORCID 0000-0003-0806-5602
Ann NordgrenDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Giedre GrigelionieneDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Maritta Hellström PiggDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.

Funding

Centre for Clinical Research SörmlandRegion Stockholm 20200500Region Stockholm 51024Region Stockholm FoUI-1000468Region Stockholm FoUI973655Sällskapet BarnavårdStiftelsen Frimurare Barnhuset i StockholmStiftelsen PromobiliaStiftelsen SällsyntafondenSwedish Childhood Cancer Fund
6 · The paper itself

Abstract

Bone morphogenetic protein 2 (BMP-2), encoded by the BMP2 gene located in chromosomal region 20p12, is a signalling protein involved in formation of bone and cartilage and other developmental processes such as cardiac and neural development. Haploinsufficiency of BMP2 has been associated with distinct facial features, short stature, skeletal malformations and cardiac abnormalities. The degree of developmental delay is still controversial. We summarise clinical and genetic findings from seven individuals with BMP2 haploinsufficiency. The study participants were identified by genetic testing and their phenotypic data was collected retrospectively from medical records. One individual had a novel frameshift variant in BMP2, and six individuals had 1.3-3.7 Mb microdeletions, including BMP2. In our cohort, delayed language development (4/5) and secretory otitis media (4/5) were common. Our results, together with previous studies, suggest that individuals with sequence variants or small microdeletions can have mild developmental delay or delay in one area (e.g., verbal development or gross motor development). We propose that global developmental delay is either a rare part or not part of the phenotype. Based on our observations, we propose that evaluation of language development and regular controls of the middle ear should be included in the surveillance of these individuals.

Indexed as

Bone Morphogenetic Protein 2Developmental DisabilitiesHaploinsufficiencyAdolescentChildChild, PreschoolFemaleGenetic Association StudiesGenotypeHumansInfantMalePhenotypeBMP2 protein, humanBone Morphogenetic Protein 2BMP2bone morphogenetic protein 2craniofacial dysmorphismgrowth hormonelanguage delaymicrodeletionshort statureskeletal anomalies

Identifiers

PMID39970956
PMCPMC12215207

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.